Common side effects (usually mild) Injection-related: Injection site redness or irritation Mild pain at injection site Temporary skin induration GH-related: Water retention (usually temporary) Mild headaches (especially initially) Increased hunger (less than GHRP-6) Tingling or numbness (rare, usually at high doses) Sleep-related: Vivid dreams (often reported, not necessarily unpleasant) Temporary sleep disturbance during adjustment Less common side effects At higher doses or prolonged use: Joint stiffness or mild carpal tunnel symptoms Flushing Dizziness Fatigue (paradoxically, sometimes) What Ipamorelin typically doesn't cause Unlike other GHRPs: No significant cortisol elevation No significant prolactin increase No intense hunger spikes No blood sugar disruption Managing side effects For water retention: Usually resolves within 2-4 weeks Reduce sodium intake Stay well-hydrated Consider reducing dose temporarily For headaches: Often occur during first week Ensure proper hydration Start with lower dose and titrate up Usually resolve with continued use For injection site reactions: Rotate injection sites Ensure proper injection technique Allow alcohol to dry before injecting Use fresh needles Contraindications Do not use Ipamorelin if you have: Active cancer or history of cancer Uncontrolled diabetes Severe cardiovascular disease Pregnancy or breastfeeding Known allergy to peptide components Use with caution if you have: Diabetes (monitor blood sugar closely) History of carpal tunnel syndrome Pituitary disorders Any condition affected by growth hormone For comprehensive safety information, see our peptide safety guide
Improves Skin Texture Regular use makes skin softer, smoother, and more refined
CJC-1295 (no DAC) + Ipamorelin Dual Peptide Blend (GHRH Analog + GHSR Agonist) Compound Name: CJC-1295 (no DAC) + Ipamorelin Classification: Research Peptides GHRH Analog + Growth Hormone Secretagogue Description: This research blend contains two laboratory peptides: CJC-1295 (no DAC) a modified growth hormonereleasing hormone (GHRH) analog Ipamorelin a selective growth hormone secretagogue receptor (GHSR) agonist Together, these compounds are widely studied in controlled research environments for their involvement in growth-hormonerelated signaling pathways, endocrine regulation, and peptide-mediated biological activity
[2] It is a tetrasubstituted version of the shortest GHRH sequence
Several risk patterns repeat across the research on these nine compounds: Injection-site reactions such as pain, redness, or swelling, reported regardless of which compound is involved
They are anecdotes
